Cancer

The latest news, views and analysis from the pharmaceutical industry’s frontline in the war on cancer. Updates on pharmaceutical and biotech oncology pipelines, regulatory decisions and market access news, and how healthcare systems needs to change to tackle one of the world’s biggest killers.

Cancer/ News/ News/ News/ Oncology/ R&D

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

Nicole Raleigh Novartis, Oncology, Pluvicto, Prostate cancer, PSMAfore study, radioligand therapy, VISION study 0 Comment

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

https://pharmaphorum.com/news/novartis-pluvicto-presents-survival-benefit-for-castration-resistant-prostate-cancer/

Cancer/ News/ News/ News/ Oncology/ Patients

AstraZeneca, MSD raise prostate cancer awareness with ‘Never Miss’ campaign

Nicole Raleigh AstraZeneca, campaign, early detection, Merck & Co, MSD, Never Miss, Oncology, Prostate cancer 0 Comment

A new global prostate cancer awareness campaign developed by biopharmaceutical companies AstraZeneca (AZ) and Merck & Co. (MSD)

AstraZeneca, MSD raise prostate cancer awareness with ‘Never Miss’ campaign

https://pharmaphorum.com/news/astrazeneca-msd-raise-prostate-cancer-awareness-with-never-miss-campaign/

Cancer/ News/ News/ Oncology

EC approves Regeneron’s Libtayo for advanced cervical cancer

Nicole Raleigh cervical cancer, European Commission, Libtayo, Regeneron, SCC 0 Comment

Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment

EC approves Regeneron’s Libtayo for advanced cervical cancer

https://pharmaphorum.com/news/ec-approves-regenerons-libtayo-for-advanced-cervical-cancer/

Cancer/ News/ News/ News/ Oncology/ R&D

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer

Nicole Raleigh ELAHERE, FDA accelerated approval, FOLR1, gynaecological cancer, immunogen, MIRASOL, Oncology, ovarian cancer, platinum-resistant, Roche 0 Comment

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian cancer

https://pharmaphorum.com/news/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer/

Cancer/ Events/ Insights/ Oncology/ Views and analysis/ World Cancer Series

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)

Nicole Raleigh BECA, cancer care, Cancer Research UK, Economist Impact, EU, Government of Malta, Innovation, MSD Italy, prevention, The Economist, World Cancer Series 0 Comment

To continue with pharmaphorum’s coverage of Day One of The Economist’s 8th Annual World Cancer Series congress in

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)

https://pharmaphorum.com/views-and-analysis/economist-impact-world-cancer-series-pharmaphorum-in-attendance-day-one-part-ii/

Cancer/ News/ News/ Oncology

Ipsen’s Cabometyx recommended by NICE for previously treated HCC

Nicole Raleigh British Liver Trust, Cabometyx, cabozantinib, HCC, Ipsen, Liver cancer, NICE, UCL Cancer Institute 0 Comment

French drugmaker Ipsen’s Cabometyx (cabozantinib) has been recommended by the National Institute for Health and Care Excellence (NICE)

Ipsen’s Cabometyx recommended by NICE for previously treated HCC

https://pharmaphorum.com/news/ipsens-cabometyx-recommended-by-nice-for-previously-treated-hcc/

Cancer/ Events/ Insights/ Oncology/ Views and analysis/ World Cancer Series

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part i)

Nicole Raleigh cancer care, European Commission, European Union, Innovation, Oncology, Stella Kyriakides, The Economist, World Cancer Series 0 Comment

It goes without saying that The Economist’s 8th Annual World Cancer Series congress was well-attended in Brussels this

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part i)

https://pharmaphorum.com/views-and-analysis/economist-impact-world-cancer-series-pharmaphorum-in-attendance/

Bristol-Myers Squibb/ Cancer/ News/ News/ News/ Oncology/ R&D/ Top pharmaceutical companies

BMS announces positive Reblozyl phase 3 results for MDS

Nicole Raleigh anaemia, blood cancer, blood transfusions, Bristol-Myers Squibb, clinical trial, myelodyplastic syndromes, Reblozyl, red blood cells 0 Comment

Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first

BMS announces positive Reblozyl phase 3 results for MDS

https://pharmaphorum.com/news/bms-announces-positive-reblozyl-phase-3-results-for-mds/

AstraZeneca/ Cancer/ Oncology/ Views & Analysis/ Views and analysis

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation

Nicole Raleigh AstraZeneca, ESMO 2022, gynaecological cancer, HRD-positive, Lynparza, olaparib, ovarian cancer, PAOLA-1, tumours 0 Comment

Last month, pharmaphorum had the chance to speak with Dr Isabelle Ray-Coquard, professor of medical oncology (specialism sarcomas

ESMO 2022 – PAOLA-1, ovarian cancer, and treatment innovation

https://pharmaphorum.com/views-and-analysis/esmo-2022-paola-1-ovarian-cancer-and-treatment-innovation/

1 2 3 4 ›»

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

Cancer

Login